Strides Pharma Science Limited has informed the Exchange about Transcript
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma reported Q1 FY26 revenue of ~INR 1,120 crores with gross margins expanding 300 bps to touch the 60% mark. EBITDA grew 15% YoY to INR 218 crores at a 19.5% margin, while operating PAT hit a record INR 114 crores, taking operational EPS to INR 12.4 (+81% YoY). The US business grew 7% YoY with the company reiterating its long-term $400 million US sales target by FY28, while other regulated markets grew 9.2% to $42 million and growth markets rose 32.2%. Net debt fell below INR 1,500 crores (INR 1,496 crores) with management targeting to be net debt-free in 3–4 years. ROCE improved to 15.1% and the cash-to-cash cycle held steady at 116 days.
Strong operational beat with margin expansion, record PAT, and steady debt reduction reinforces the turnaround story and supports the $400M US guidance. Near-term overhangs remain—US tariff risk, weak access market due to USAID funding cuts, and UK pricing pressure—though management indicated these are manageable.